Core Insights - The Tianzhu Comprehensive Bonded Zone is establishing a rare disease drug guarantee pilot area by 2025, aiming to enhance open innovation and facilitate the import of rare disease medications, with a cumulative import value reaching 27.043 billion yuan, ranking first in the country [1] - Approximately 70% of rare diseases manifest in childhood, and the current domestic supply of rare disease drugs is limited, leading to significant challenges for patients due to lengthy and costly import processes [1][2] - The Tianzhu Comprehensive Bonded Zone is implementing measures such as pre-assessment, tracking review, and 24-hour customs clearance to streamline the import and distribution of rare disease medications, ensuring timely access for patients [1] Group 1 - The Tianzhu Comprehensive Bonded Zone aims to transition from "people waiting for drugs" to "drugs waiting for people" by improving the policy support system for rare disease treatments [2] - By 2025, the zone plans to establish a multi-tiered medication guarantee system, including the inclusion of 10 urgently needed rare disease drugs in the Beijing Universal Health Insurance overseas special drug list [2] - The construction of the rare disease drug guarantee pilot area is expected to attract over 30 domestic and international pharmaceutical companies, contributing to a medical trade scale of 100.093 billion yuan by 2025 [2]

Core Viewpoint - An innovative imported drug for rare diseases has been prescribed for the first time in mainland China, providing new hope for patients with primary biliary cholangitis [1] Group 1: Drug Introduction and Impact - The drug was introduced at Beijing Friendship Hospital, benefiting a patient with primary biliary cholangitis, a chronic liver disease classified as a rare disease [1] - The drug is expected to effectively improve symptoms and prognosis for patients, offering a safer treatment option compared to existing therapies [1] - The rapid introduction of the drug was facilitated by a temporary import policy for urgently needed clinical drugs in the Tianzhu Comprehensive Bonded Zone [1] Group 2: Regulatory and Market Context - The drug has already been approved for sale abroad and is currently only available for prescription at Beijing Friendship Hospital in mainland China [1] - The Tianzhu Comprehensive Bonded Zone is the first airport-type comprehensive bonded zone in the country, which aims to explore the import of rare disease drugs not yet registered in China [1] - In November 2023, the State Council approved the establishment of a rare disease drug guarantee pilot area in Tianzhu, further addressing the clinical medication needs for rare diseases [1]

Group 1 - Beijing has launched its first public welfare medical insurance for newborns with rare diseases, providing health protection for the public [1] - The insurance is developed by the Capital Airport Economic Zone Management Committee, PICC Beijing Branch, and Beijing Life Insurance, covering 14 overseas special drugs and 8 domestic special drugs [1] - The initiative aims to enhance the accessibility and affordability of rare disease treatments through a combination of government guidance, enterprise underwriting, and social participation [1] Group 2 - By the end of 2023, relevant authorities approved the establishment of a rare disease drug guarantee pilot zone in the Tianzhu Comprehensive Bonded Zone, optimizing mechanisms and processes [2] - A total of 26 clinically needed imported drugs, including those for rare diseases, have been approved, benefiting over 4,900 patients [2] - From January to August 2025, the value of imported rare disease drugs exceeded 15.523 billion yuan [2]